Previous studies from our laboratory and those of others suggested the possibility that the T-cell antigen receptor a (TCRa) chain from some T cells can be released in a soluble form and can have antigen-specific immunoregulatory activity. We A far more controversial mechanism of T cell-mediated immunosuppression involves antigen-specific T cell factors (reviewed in refs. 5-9) that bind antigen and produce an immunoregulatory effect. T-cell hybridomas producing such antigen-specific regulatory molecules were generated and analyzed, and attempts to characterize the antigen-specific factors were made. However, a failure to consistently detect rearrangement of the TCR,B chain genes in such hybridomas (10, 11) contributed to skepticism regarding the existence of such T cells and factors (12). The issue was further confused by the observation that suppressor T-cell hybridomas and transformed T-cell lines rearrange and express TCRa genes (13, 14) . Therefore, proposals to the effect that suppressor T cells use a novel T-cell receptor (15) were not substantiated.
By the late 1960s it was clear to most cellular immunologists that T cells are crucial in the immune response as effector cells in cell-mediated responses and as helper cells in both humoral and cell-mediated responses. It was at about this time that an additional immunologic role for T cells was proposed: the suppression of immune responses. Since the original descriptions by Gershon and Kondo (reviewed in ref. 1) , T cells capable of suppressing immune responses have been described in a wide range of systems. One problem that arose in this regard was that the effects were all attributed to "suppressor T cells," implying that there was only one mechanism (and cell type) that could produce such effects. We now know that there are a number of ways in which T cells can inhibit immune responses (e.g., see refs. 1 
and 2).
Most T lymphocytes bear T-cell antigen receptors (TCRs) composed of an a and a 13 chain (TCRa and TCRj3), and it is this receptor that is responsible for recognition of a complex ligand composed of an antigen peptide held in a major histocompatibility molecule on antigen-presenting cells (3) . Upon recognition of this specific ligand, CD4+ T cells respond by the production of cytokines that are often capable of inhibiting some types of immune responses (1, 4) . This mechanism of antigen-specific T cell-mediated suppression is well established.
A far more controversial mechanism of T cell-mediated immunosuppression involves antigen-specific T cell factors (reviewed in refs. [5] [6] [7] [8] [9] ) that bind antigen and produce an immunoregulatory effect. T-cell hybridomas producing such antigen-specific regulatory molecules were generated and analyzed, and attempts to characterize the antigen-specific factors were made. However, a failure to consistently detect rearrangement of the TCR,B chain genes in such hybridomas (10, 11) contributed to skepticism regarding the existence of such T cells and factors (12) . The issue was further confused by the observation that suppressor T-cell hybridomas and transformed T-cell lines rearrange and express TCRa genes (13, 14) . Therefore, proposals to the effect that suppressor T cells use a novel T-cell receptor (15) were not substantiated.
Progress has nevertheless been made towards resolving the paradox posed by T cell-derived, antigen-specific immunoregulatory factors. Several laboratories have found that such factors bear determinants recognized by anti-TCRa antibody (16) (17) (18) (19) , and the molecule resolves as having a molecular mass of 46 kDa, as does TCRa (19) . TCRa cDNA from cells capable of producing antigen-specific factors transfers the ability to make such factors when expressed in other T cells (20, 21) . Thus, some TCRa molecules appear to have antigen-specific immunoregulatory activity and can apparently exist in a cellfree form, probably in a complex with other molecules. Charged residues within the TCRa transmembrane region permit the molecule to exist in either a membrane form (stabilized by other-molecules) or a soluble form (22) (again, probably stabilized by other molecules).
Previously, we reported that a helper T-cell hybridoma, A1.1, specific for a synthetic polypeptide antigen called "poly 18"-poly[Glu-Tyr-Lys-(Glu-Tyr-Ala)5]-plus I-Ad constitutively releases a poly 18-specific immunoregulatory activity detected in an in vitro assay (23) . An examination of the antigenic fine specificity of this cell-free activity revealed a correspondence to the specificity of the A1.1 TCR (19, 23) , and the activity was bound and eluted from an anti-TCRa antibody (19) . A relationship with the TCR was further established by the use of antisense oligodeoxynucleotides corresponding to the TCR variable region a chain (Va) of A1.1 (24) . Finally, we found that expression of A1.1 TCRa cDNA in other T-cell hybridomas conferred the ability to produce the soluble, antigen-specific factor (20) . These data strongly implicate the AM. TCRa The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. the nonrandom synthetic polypeptide poly 18 were kindly provided by Bhagirath Singh (University of Western Ontario) or by Kirin Pharmaceuticals (Maeabashi, Japan). Peptides were coupled to SRBC by using chromic chloride as described (19, 23 (25) (provided by R. Lerner of Scripps) to produce a fusion protein composed of the TCRa region and coat protein VIII (26) . The inserts were cloned into Bluescript SK (Stratagene) for in vitro expression. In all cases, RNA was expressed from the phage T7 promoter of Bluescript, and protein was translated using TNT T7-coupled reticulocyte lysate system (Promega).
[35S]Methionine (DuPont) was added to-the reactions, and protein was resolved by SDS/PAGE.
In Vitro Assay for Antigen-Specific Immunoregulatory Activity. "Accessory supernatants" required for A1.1 suppressor activity analysis were prepared as described (19, 23) . Briefly, C57BL/6 mice were immunized twice with 0.2 ml of 20% SRBC, and immunoglobulin-free splenocytes (1 X 107 cells per ml) were then cultured in RPMI 1640 medium with 10% (vol/vol) FCS. After 48 hr the supernatants were collected, and the material was then extensively absorbed with SRBC at 4°C. To assay for antigen-specific suppressor activity of TCRa or supernatants of A1.1, a simple antigen-specific system was employed as previously described (19, 23) . Spleen cells (1 x 107) from C57BL/6 mice were placed into 1-ml cultures in RPMI 1640 medium supplemented with 10% FCS and 50 ,M 2-mercaptoethanol. Each culture received 50 ,ll of 1% peptidecoupled SRBC. TCRa (diluted 1:1000) with or without accessory supernatant was added to the cultures and incubated at 37°C in humidified 92% air/8% CO2. Anti-SRBC plaqueforming cells (without peptides) were assessed 5 days later. In no case was any suppressive effect observed in the absence of accessory supernatant (not shown). All values (controls and experimental) reported in this paper are from cultures containing accessory supernatant.
Objectivity of Results. Assessment of plaque-forming cells is visual and thus necessarily subjective; therefore, the majority of the experiments described in this paper were performed under masked conditions. For antigen-specificity controls, peptides or saline were coded prior to coupling to SRBC. For experiments with truncated or chimeric TCRa molecules, the 3005 products of the IVTT (including negative controls) were coded prior to addition to the assay culture.
Binding of TCRa to Peptide-Coupled SRBC. Fifty microliters of 10% peptide-coupled SRBC (see above) was mixed with 8 ,ul of [35S]methionine-labeled, full-length A1.1 TCRa and incubated for 2 hr at room temperature with shaking. Cells were then washed, and cell pellets were directly lysed in reducing SDS sample buffer. Samples were incubated for 5 min at 95°C prior to separation on a SDS/PAGE 10-20% gradient gel (Bio-Rad).
RESULTS
IVTT AM.1 TCRa Displays Antigen-Specific Immunoregulatory Activity. Proteins produced in vitro from A1.1 TCRa or TCR,B cDNA were assessed by SDS/PAGE as shown in Fig. 1 Upper. We examined the ability of these proteins to regulate an in vitro immune response. A1.1 TCRa displayed the antigenspecific immunoregulatory activity we had previously observed in supernatants of A1.1 cells (19) , whereas A1.1 TCR,B did not (Fig. 1 Lower) . The antigen-specificity of this material was then tested in a series of experiments with antigenic peptides related to the poly 18 antigen. We observed (Fig. 2 Upper) that peptides substituted by alanine at residue 3 or residue 10 failed to act as targets for the TCRa immunoregulatory activity, whereas unsubstituted peptides did. This is the pattern of specificity previously observed for both the A1.1 TCR and for the soluble immunoregulatory activity (19, 20) . Radiolabeled A1.1 TCRa was bound by SRBC coupled with the antigenic peptide but not with peptide substituted by alanine at residue 10 ( Fig. 2 Lower) .
This direct binding to antigen was also detected in our bioassay by two methods. First, we found that the antigencoupled SRBC that were incubated with A1.1 TCRa carried the suppressive activity into the bioassay (i.e., the anti-SRBC response to these was inhibited) (results not shown). Second 18 and substituted with alanine at residue 10 (P18 A10; Glu-Tyr-Lys-(Glu-Tyr-Ala)2-Ala-Tyr-Ala-Glu-Tyr-Ala); 3, SRBC coupled with antigenic peptide based on poly 18 (P18; Glu-Tyr-Lys-(Glu-Tyr-Ala)4-Glu-Tyr-Lys); 4, TCRa directly loaded into gel. fashion ('60% inhibition was reduced to 37% by 10 ,ug of free peptide per ml and to 2% by 50 ,ug/ml) (data not shown).
To determine the amount of A1. (Fig. 4 Top). We then constructed additional truncations by PCR, and the proteins resulting from these forms, VJ-VJC40, are shown in Fig. 3 Bottom. The bioactivity of these truncated proteins was tested in a series of experiments shown in Fig. 4 Middle. We found that in order for the A1.1 TCRa molecule to function in our bioassay, at least 30 amino acids of the Cal domain were required in addition to the VJ regions. TCRa molecules including only the first 20 amino acids of Ca consistently failed to function. We then generated a TCRa molecule containing the VJ regions plus the first 25 amino acids of Ca. This construct yielded a protein of the expected size after IVTT (not shown). As shown in Fig.  4 Bottom, it also displayed biological activity in our assay system.
The Requirement for a Portion of TCR Cal Domain Is Probably Not Due To a Simple Structural Effect. We engineered chimeric molecules composed of VJa ± Ca in tandem with a phage coat protein, cpVIII (25, 26) . The IVTT chimeric proteins were of the predicted sizes, -25 kDa for VJa-cpVIII and -36 kDa for VJCa-cpVIII (Fig. 5 Upper) . When Fig. 3 Middle was tested in our bioassay. All results from three experiments are shown. In each experiment, all products of the IVTT reactions (including no template, luciferase cDNA template, fulllength or truncated TCRa) were masked prior to use in the experiment. (Middle) Regulatory activity of the truncated TCRa proteins generated as in Fig. 3 Bottom was examined. All results from five experiments are shown. In each experiment, all products of the IVTT reactions (including no template, luciferase cDNA template, fulllength or truncated TCRa) were masked prior to use in the experiment. (Bottom) Activity of TCRa truncated at C25. A TCRa protein extending from the leader to C25 was generated by PCR and IVTT, and the resulting protein resolved at the expected relative molecular mass (not shown). Immunoregulatory activity was assessed as in Top and Middle, with the indicated translation products masked prior to addition to the culture. the in vitro assay system, the chimeric protein composed of VJCa plus cpVIII displayed function, while that composed of only VJa plus cpVIII did not (Fig. 5 specific binding and immunoregulatory activity. This direct binding appears to be a requirement for the inhibitory effect, since peptides that are not bound by the TCRa (Fig. 2 Lower) do not function as targets in the bioassay (Fig. 2 Upper), and free antigenic peptide can compete with the SRBC-bound peptides and thus block the inhibition of the anti-SRBC response in this system (results not shown but described above).
We found that in addition to VJa, the first 25 amino acids of the C region were necessary for the expressed protein to have function (Fig. 4) . This requirement for a portion of Ca probably does not represent a simple need for protein stability. Chimeric proteins generated by fusion of TCRa with the cpVIII protein of filamentous phage were functional in our assay system only when the Ca region was present (Fig. 5 Lower). However, we have found that phage.displaying chimeric proteins composed of either A1.1 TCR VJa or VJCa plus CPVIII (as in Fig. 4 ) yield phage that bind equivalently to the specific peptides (T.O., D. Laface, G.B., T.B., N. Honma, T. Mikayama, A. Altman, and D.R.G., unpublished data). Since VJa-cpVIII binds peptide but does not function in our assay system and VJCa-cpVIII does both, it is unlikely that the role of the Ca region in the biological activity we observe is simply to stabilize VJa.
An interesting possibility is that the Ca is required for interaction with other proteins to mediate antigen-specific effects. Research from several laboratories suggests that such interactions with molecules likely to be TCRa are a common feature of antigen-specific immunoregulation (16-21, 31 ). For example, Iwata et al. (16) described an antigen-specific immunoregulatory factor composed of a molecule bearing a TCRa determinant complexed with an antigen-nonspecific cytokinelike activity, glycosylation inhibiting factor (GIF). Similarly, Bristow and Flood (31) described a molecule bearing a TCRa determinant complexed with an elastase activity.
Such an interaction might be important for release of the TCRa molecule as well. The TCRa transmembrane region, when substituted for the transmembrane region of CD4, results in secretion of a soluble CD4 molecule from cells (21) . In the absence of stabilizing CD3 molecules, TCRa is released into the lumen of the endoplasmic reticulum but is degraded there or in the Golgi (22, 32) . Nevertheless, TCRa is produced in excess in T cells (32) , and it is thus possible that additional molecules can stabilize the soluble TCRa molecules and allow their secretion from the cell.
It remains unclear whether immune regulation by TCRa represents an important physiological mechanism. Although our work relies entirely upon in vitro assays, other laboratories have provided support for the idea that TCRa molecules can participate in antigen-specific regulation in vivo (17, 21, 33) . Whether soluble TCRa molecules can be identified in serum (e.g., see ref. 34 ) and whether they have important biological functions should be determined.
